stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) Return on assets
NewAmsterdam Pharma Company N.V.'s return on assets over the twelve months to 30 September 2026 was −27.8%, down 2.8 percentage points from fiscal 2025 (−25.0%). Over the past ten years it has ranged from −42.9% (fiscal 2023) to 2.99% (fiscal 2021); the current reading is higher than 33% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −25.0% | 14.93 |
| FY2024 | −39.9% | 2.98 |
| FY2023 | −42.9% | (35.54) |
| FY2022 | −7.32% | (7.32) |
| FY2022 | 0.00% | (2.99) |
| FY2021 | 2.99% | 2.99 |
| FY2021 | 0.00% | (0.03) |
| FY2020 | 0.03% | (0.03) |
| FY2020 | 0.06% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ADMA ADMA Biologics Inc compare | 28.0% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −18.2% |
| XNCR Xencor, Inc. compare | −20.4% |
| NAMS NewAmsterdam Pharma Company N.V. | −27.8% |
| MBX MBX Biosciences, Inc. compare | −31.3% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −36.3% |
| PVLA Palvella Therapeutics, Inc. compare | −37.7% |
| CLDX Celldex Therapeutics, Inc. compare | −40.8% |
| PHVS Pharvaris N.V. compare | −64.4% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement